Le Lézard
Classified in: Health, Science and technology, Business
Subject: CON

DarioHealth Chosen by Regional Primary Care Provider PeopleOne Health as its Digital Behavioral Health Partner

NEW YORK, Aug. 31, 2021 /PRNewswire/ -- DarioHealth Corp. (Nasdaq: DRIO), a leader in the global digital therapeutics (DTx) market, announced today that it has been selected by regional primary care provider PeopleOne Health to be the digital behavioral health solution of choice for patients beginning this September. This contract represents Dario's continuing growth in the provider market, leveraging its expanded product portfolio.

DarioHealth Logo

PeopleOne Health is integrating Dario's digital behavioral health solution to address a wide range of mental health needs to support high-value, holistic care to its growing base of direct consumer and employer partner populations. Dario's solution uses AI-driven screening to assess and triage individuals to the most appropriate care, including integrated digital tools and coaching, giving patients a seamless path from primary care to proven mental health support.

"In order to stay competitive, providers require modern solutions that effectively manage the whole health of a patient, and we believe that Dario's rapid growth reflects strong alignment with market needs across our suite of solutions. The agreement with PeopleOne Health represents new proof of value for our digital behavioral health solution as an intervention in point-of-care settings where most mental health needs are diagnosed today," said Rick Anderson, President and General Manager of North America at DarioHealth.

About DarioHealth Corp.

DarioHealth Corp. (Nasdaq: DRIO) is a leading global digital therapeutics company revolutionizing how people with chronic conditions manage their health. DarioHealth offers one of the most comprehensive digital therapeutics solutions on the market - covering multiple chronic conditions including diabetes, hypertension, weight management, musculoskeletal and behavioral health within one integrated technology platform.

Dario's next-generation, AI-powered, digital therapeutic platform supports more than just an individual's disease. Dario provides adaptive, personalized experiences that drive behavior change through evidence-based interventions, intuitive, clinically proven digital tools, high-quality software, and coaching to help individuals improve health and sustain meaningful outcomes.

Dario's unique user-centric approach to product design and engagement creates an unparalleled experience that is highly rated by users and delivers sustainable results.

The company's cross-functional team operates at the intersection of life sciences, behavioral science, and software technology and utilizes a performance-based approach to improve its users' health.

On the path to better health, Dario makes the right thing to do the easy thing to do. To learn more about DarioHealth and its digital health solutions, or for more information, visit http://dariohealth.com.

Cautionary Note Regarding Forward-Looking Statements

This news release and the statements of representatives and partners of DarioHealth Corp. related thereto contain or may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Statements that are not statements of historical fact may be deemed to be forward-looking statements. For example, the Company is using forward-looking statements in this press release when it discusses the timing of the implementation of its platform with the provider based in Pennsylvania and the belief that its rapid growth reflects strong alignment with market needs across its suite of solutions. Without limiting the generality of the foregoing, words such as "plan," "project," "potential," "seek," "may," "will," "expect," "believe," "anticipate," "intend," "could," "estimate" or "continue" are intended to identify forward-looking statements. Readers are cautioned that certain important factors may affect the Company's actual results and could cause such results to differ materially from any forward-looking statements that may be made in this news release. Factors that may affect the Company's results include, but are not limited to, regulatory approvals, product demand, market acceptance, impact of competitive products and prices, product development, commercialization or technological difficulties, the success or failure of negotiations and trade, legal, social and economic risks, and the risks associated with the adequacy of existing cash resources. Additional factors that could cause or contribute to differences between the Company's actual results and forward-looking statements include, but are not limited to, those risks discussed in the Company's filings with the U.S. Securities and Exchange Commission. Readers are cautioned that actual results (including, without limitation, the timing for and results of the Company's commercial and regulatory plans for Dariotm as described herein) may differ significantly from those set forth in the forward-looking statements. The Company undertakes no obligation to publicly update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.

Logo - https://mma.prnewswire.com/media/544126/DarioHealth_Logo.jpg

DarioHealth Corporate Contact:
Suzanne Bedell
VP Marketing

Media Contact:
Josephine Galatioto

SOURCE DarioHealth Corp.

These press releases may also interest you

at 08:24
Targovax ASA today announces that members of its executive management team are invited to present and participate in upcoming conferences. Økonomisk Ugebrev's Life Science Investor conferenceDate: 20 October 2021Presenter: Lone Ottesen (CDO)Time:...

at 08:20
CDISC announced that it is collaborating with OpenClinica to improve data collection in clinical studies conducted by academic institutions and researchers with the goal of driving research forward. The collaboration came about as a result of...

at 08:20
Availity, one the nation's largest real-time health information networks, announced today that Jim McNary has joined the company as chief operating officer (COO). As COO, McNary is responsible for leading cross-departmental operations, refining...

at 08:18
BrainScope today announced a new system-wide agreement with Yankee Alliance to make BrainScope's innovative point-of-care neuro-technology system available to the 18,000 members, including over 5,000 outpatient facilities and senior centers, in...

at 08:15
Aurion Biotech, whose mission is to cure blindness by developing a differentiated platform of advanced therapies to treat ocular diseases, today announced the company's medical advisory board, composed of the world's most eminent ophthalmologists....

at 08:10
ReCode Therapeutics, a biopharmaceutical company pioneering disease-modifying genetic medicines using its proprietary LNP delivery platform, today announced that it will present preclinical data from its mRNA-based therapeutic program for cystic...

News published on 31 august 2021 at 07:00 and distributed by: